CN117794527A - 新型活化amp的蛋白激酶活化剂 - Google Patents
新型活化amp的蛋白激酶活化剂 Download PDFInfo
- Publication number
- CN117794527A CN117794527A CN202280053568.2A CN202280053568A CN117794527A CN 117794527 A CN117794527 A CN 117794527A CN 202280053568 A CN202280053568 A CN 202280053568A CN 117794527 A CN117794527 A CN 117794527A
- Authority
- CN
- China
- Prior art keywords
- compound
- group
- substituted
- mmol
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021-094481 | 2021-06-04 | ||
| JP2021094481 | 2021-06-04 | ||
| PCT/JP2022/023390 WO2022255499A1 (ja) | 2021-06-04 | 2022-06-03 | 新規なamp活性化プロテインキナーゼ活性化剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117794527A true CN117794527A (zh) | 2024-03-29 |
Family
ID=84322602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280053568.2A Pending CN117794527A (zh) | 2021-06-04 | 2022-06-03 | 新型活化amp的蛋白激酶活化剂 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12622891B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4349331A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2022255499A1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN117794527A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022255499A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004043366A2 (en) | 2002-11-06 | 2004-05-27 | Smithkline Beecham Corporation | Sulfonamides |
| TW200424174A (en) | 2003-02-06 | 2004-11-16 | Hoffmann La Roche | New TP diamide |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| ES2328820T3 (es) | 2003-10-17 | 2009-11-18 | Astrazeneca Ab | Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer. |
| DE102004039876A1 (de) | 2004-06-23 | 2006-01-26 | Lanxess Deutschland Gmbh | Herstellung von fluorierten 1,3-Benzodioxanen |
| JP2008007405A (ja) | 2004-12-07 | 2008-01-17 | Takeda Chem Ind Ltd | カルボキサミド誘導体 |
| CA2598458A1 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity |
| JP2011178728A (ja) | 2010-03-02 | 2011-09-15 | Kobe Univ | Ampk活性化剤、glut4活性化剤、およびそれらを用いた医薬品・飲食品 |
| JP2013212994A (ja) * | 2010-06-22 | 2013-10-17 | Sanwa Kagaku Kenkyusho Co Ltd | 新規チオフェンカルボキサミド誘導体及びその医薬用途 |
| US20130345243A1 (en) | 2011-03-07 | 2013-12-26 | Glaxosmithkline Llc | 1h-pyrollo[3,2-d]pyrimidinedione derivatives |
| WO2014069426A1 (ja) * | 2012-10-31 | 2014-05-08 | 塩野義製薬株式会社 | Ampk活性化作用を有するベンズイミダゾールおよびアザベンズイミダゾール誘導体 |
| CA2950119C (en) | 2013-06-18 | 2021-09-14 | Albert Einstein College Of Medicine, Inc. | Treatment of obesity and pulmonary arterial hypertension |
| SG11201908817WA (en) | 2017-03-21 | 2019-10-30 | Fujifilm Corp | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound |
| JP7131034B2 (ja) | 2018-03-30 | 2022-09-06 | 株式会社三洋物産 | 遊技機 |
| JP7185226B2 (ja) * | 2018-11-22 | 2022-12-07 | 国立大学法人 鹿児島大学 | 1,5-アンヒドロフルクトース誘導体を含むampk活性化剤 |
| US11299582B2 (en) * | 2019-04-29 | 2022-04-12 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Breathable elastomeric composites with tether-containing conducting polymers for nanoscale diffusion control and protection |
-
2022
- 2022-06-03 JP JP2023525939A patent/JPWO2022255499A1/ja active Pending
- 2022-06-03 EP EP22816244.2A patent/EP4349331A4/en active Pending
- 2022-06-03 CN CN202280053568.2A patent/CN117794527A/zh active Pending
- 2022-06-03 WO PCT/JP2022/023390 patent/WO2022255499A1/ja not_active Ceased
- 2022-06-03 US US18/566,730 patent/US12622891B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4349331A4 (en) | 2025-06-11 |
| JPWO2022255499A1 (cg-RX-API-DMAC7.html) | 2022-12-08 |
| WO2022255499A1 (ja) | 2022-12-08 |
| US12622891B2 (en) | 2026-05-12 |
| EP4349331A1 (en) | 2024-04-10 |
| US20240277657A1 (en) | 2024-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102533599B1 (ko) | 단백질 티로신 포스파타제 억제제 및 이의 사용 방법 | |
| CN109563075B (zh) | Tlr7/8拮抗剂及其用途 | |
| WO2021078301A1 (zh) | 蛋白降解剂及其在疾病治疗中的应用 | |
| CN107074859B (zh) | 用于治疗癌症的作为吲哚胺-2,3-双加氧酶(ido)拮抗剂的环己基乙基取代的二氮杂-和三氮杂-三环化合物 | |
| KR20240101561A (ko) | Kras의 저해제로서의 퀴놀린 화합물 | |
| JP2024524524A (ja) | 窒素含有複素環化合物、その製造方法、中間体及び使用 | |
| MD4219492T2 (ro) | Compuși heterociclici ca imunomodulatori | |
| CN116348455A (zh) | 蛋白质酪氨酸磷酸酶抑制剂和其使用方法 | |
| KR20210137025A (ko) | 치료제 및 치료 방법 | |
| JP2023508097A (ja) | タンパク質分解剤化合物の製造方法及び使用 | |
| IL322897A (en) | Camptothecin derivatives and conjugates, methods for their preparation and medical uses | |
| CN101754966A (zh) | 丙型肝炎病毒抑制剂 | |
| CN102459239A (zh) | 丙型肝炎病毒抑制剂 | |
| WO2021190417A1 (zh) | 新型氨基嘧啶类egfr抑制剂 | |
| JP7654075B2 (ja) | 貧血およびがんの処置のためのvhl阻害剤としての1-(2-(4-シクロプロピル-1h-1,2,3-トリアゾール-1-イル)アセチル)-4-ヒドロキシ-n-(ベンジル)ピロリジンe-2-カルボキサミド誘導体 | |
| WO2023141852A1 (zh) | Cdk2抑制剂及其制备方法和用途 | |
| CN115867545A (zh) | 抗病毒素1,3-二氧代茚化合物 | |
| WO2023088493A1 (zh) | 一种呋喃并吡啶酮类化合物及其应用 | |
| JP2025523332A (ja) | エキサテカン由来adcリンカー-ペイロード、医薬組成物、及びそれの使用 | |
| CN108403698A (zh) | 用于治疗细菌感染的方法和组合物 | |
| CN114685601B (zh) | 雄性激素受体结合分子及其用途 | |
| WO2025149012A1 (zh) | Dolastatin衍生物及其制备方法和应用 | |
| KR20070062569A (ko) | 테모졸로마이드 에스테르를 포함하는 약학 조성물 | |
| EP4349331A1 (en) | Novel amp-activated protein kinase activator | |
| KR20240121239A (ko) | 질환 치료를 위한 이환식 화합물의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |